These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 38178730)
1. A Study on the Incidence and Prevalence of 5q Spinal Muscular Atrophy in Canada Using Multiple Data Sources. Price TR; Hodgkinson V; Westbury G; Korngut L; Innes MA; Marshall CR; Nelson TN; Huang L; Parboosingh J; Mah JK Can J Neurol Sci; 2024 Jan; ():1-12. PubMed ID: 38178730 [TBL] [Abstract][Full Text] [Related]
2. Nusinersen: A Review in 5q Spinal Muscular Atrophy. Hoy SM CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360 [TBL] [Abstract][Full Text] [Related]
3. The Japan Registry for Adult Subjects of Spinal Muscular Atrophy (jREACT-SMA): Protocol for a Longitudinal Observational Study. Sahashi K; Hashizume A; Kuwatsuka Y; Chinen M; Saotome-Nakamura A; Ando M; Katsuno M JMIR Res Protoc; 2022 Dec; 11(12):e38878. PubMed ID: 36520510 [TBL] [Abstract][Full Text] [Related]
4. Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence. Hjartarson HT; Nathorst-Böös K; Sejersen T Drug Des Devel Ther; 2022; 16():1865-1883. PubMed ID: 35734367 [TBL] [Abstract][Full Text] [Related]
5. Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies. Angilletta I; Ferrante R; Giansante R; Lombardi L; Babore A; Dell'Elice A; Alessandrelli E; Notarangelo S; Ranaudo M; Palmarini C; De Laurenzi V; Stuppia L; Rossi C Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834320 [TBL] [Abstract][Full Text] [Related]
6. Survey of patients with spinal muscular atrophy on the island of Shikoku, Japan. Okamoto K; Motoki T; Saito I; Urate R; Aibara K; Jogamoto T; Fukuda M; Wakamoto H; Maniwa S; Kondo Y; Toda Y; Goji A; Mori T; Soga T; Konishi Y; Nagai S; Takami Y; Tokorodani C; Nishiuchi R; Usui D; Ando R; Tada S; Yamanishi Y; Nagai M; Arakawa R; Saito K; Nishio H; Ishii E; Eguchi M Brain Dev; 2020 Sep; 42(8):594-602. PubMed ID: 32505480 [TBL] [Abstract][Full Text] [Related]
7. Epidemiological investigation of spinal muscular atrophy in Japan. Ito M; Yamauchi A; Urano M; Kato T; Matsuo M; Nakashima K; Saito K Brain Dev; 2022 Jan; 44(1):2-16. PubMed ID: 34452804 [TBL] [Abstract][Full Text] [Related]
9. Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada. Chen G; Sharif B; Gerber B; Farris MS; Cowling T; Cabalteja C; Wu JW; Maturi B; Klein-Panneton K; Jean K Mah J Med Econ; 2021 Nov; 24(sup1):51-59. PubMed ID: 34906030 [TBL] [Abstract][Full Text] [Related]
10. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis. Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305 [TBL] [Abstract][Full Text] [Related]
11. Drug treatment for spinal muscular atrophy type I. Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542 [TBL] [Abstract][Full Text] [Related]
12. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy. Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J; Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854 [TBL] [Abstract][Full Text] [Related]
13. Nusinersen treatment of spinal muscular atrophy - a systematic review. Albrechtsen SS; Born AP; Boesen MS Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069 [TBL] [Abstract][Full Text] [Related]
15. Neurological and Psychiatric Aspects of Biological Markers for the Provision of Medical Care to Patients with Spinal Muscular Atrophy 5q. Gayduk AJ; Syunyakov T; Gazheva AV; Strelnik A; Chigareva O; Kuznetsov A; Kokorev D; Sustretov A; Cumming P; Vlasov YV Psychiatr Danub; 2023 Oct; 35(Suppl 2):322-328. PubMed ID: 37800249 [TBL] [Abstract][Full Text] [Related]
16. Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada. McMillan HJ; Gerber B; Cowling T; Khuu W; Mayer M; Wu JW; Maturi B; Klein-Panneton K; Cabalteja C; Lochmüller H J Neuromuscul Dis; 2021; 8(4):553-568. PubMed ID: 33749617 [TBL] [Abstract][Full Text] [Related]
17. Spinal muscular atrophy genetic epidemiology and the case for premarital genomic screening in Arab populations. Rabea F; El Naofal M; Chekroun I; Khalaf M; Zaabi NA; AlZaabi K; ElHalik M; Dash S; El Saba Y; Ali A; Abraham S; Fathi K; Shekhy J; Aswad SG; Elbashir H; Alkuraya F; Loney T; Alsheikh-Ali A; Khayat AA; Abou Tayoun A Commun Med (Lond); 2024 Jun; 4(1):119. PubMed ID: 38879606 [TBL] [Abstract][Full Text] [Related]